FTI-2628
FTI-2628 is an antimalarial agent and a farnesyl transferase inhibitor, with an IC50 of 41.7 nM against TbPET. FTI-2628 attenuates glucose-stimulated insulin secretion. FTI-2628 exhibits antimalarial activity against Trypanosoma brucei.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 655234-81-4
- Fòrmula: C31H34N4O3S
- Peso molecular:542.69
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Trypanosoma |
In Vitro
Chemical Information
-
No. CAS 655234-81-4
-
Peso molecular 542.69
-
Fòrmula C31H34N4O3S
-
SMILES
O=C(OCC1=CC=CC=C1)[C@H](CCSC)NC(C2=C(C3=C(C=CC=C3)C)C=C(C=C2)CNCC4=CN=CN4)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
Pureza y Documentación
Referencias
[1]. Ohkanda J, et al. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. Journal of medicinal chemistry. 2004 Jan 15;47(2):432-45. [Content Brief]
[2]. Matti A, et al. Protein farnesylation is requisite for mitochondrial fuel-induced insulin release: further evidence to link reactive oxygen species generation to insulin secretion in pancreatic β-cells. Islets. 2012 Jan-Feb;4(1):74-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FTI-2628 Related Classifications
HY-183458 Related Classifications
Powered by Bioz